Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AMECRYS

Financiado

Cerrado

Revolutionising Downstream Processing of Monoclonal Antibodies by Continuous Tem...

Revolutionising Downstream Processing of Monoclonal Antibodies by Continuous Template Assisted Membrane Crystallization Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually... ver más

31/03/2021

CNR

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-03-31

FETOPEN-RIA-2014-2015: FET-Open research projects

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

CNR

608.07K€ | Lider

INSTITUTO GRIFOLS, S.A

480.71K€ | Participante

CNRS

274.12K€ | Participante

Proyectos interesantes

BIOPURE

Medical Technol...

Chemical Engine...

2M€ Cerrado

nextBioPharmDSP

Medical Technol...

Chemical Engine...

11M€ Cerrado

DESARROLLO Y OPTIMIZACIÓN DEL PROCESO DE SÍNT...

Medical Technol...

Chemical Engine...

759K€ Cerrado

PTQ-08-03-08751

Medical Technol...

Chemical Engine...

75K€ Cerrado

FAST-BM

Medical Technol...

Biotechnology

71K€ Cerrado

PLASTICBIOPHARMAPUR

Chemical Engine...

Medical Technol...

179K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 58 meses Fecha Inicio: 2016-05-13
Fecha Fin: 2021-03-31

Líder del proyecto

CONSIGLIO NAZIONALE DELLE RICERCHE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually achieved chromatographically, with all of its disadvantages including high buffer requirements, large footprint, reuse and storage of resin studies as well as costs. Traditional DSP based on batch chromatography contribute ca. 66% of the total production cost of anti-cancer monoclonal antibodies (mAbs). Largely contributing to this is the cost of chromatography media; for instance, the cost of 1 L of protein A resin with binding capacity of 20-70 g mAb is about 25000 Eur. By a visionary and ambitious combination of the emerging Continuous Manufacturing Paradigm with innovative Membrane Crystallization Technology and the selective nanotemplate-recognitions directly from the fermentation broth, the AMECRYS Network aims to develop a new Continuous Template-Assisted Membrane Crystallizer in order to revolutionize the DSP platform for mAbs production, thus achieving unprecedented purification and manufacturing efficiencies. Major research challenges will include: i) the synthesis of 3D-nanotemplates with specific molecular recognition ability towards mAbs from complex solutions; ii) the development of tailored macroporous fluoropolymer membranes for advanced control of selective heterogeneous nucleation; iii) the design of multilevel microfluidic devices for high-throughput mAb crystallization screening in a wide range of conditions under continuous flow (pharma-on-a-chip concept); iv) technology scale-up to a L-scale continuous prototype designed with recognition of QS/GMP compliance for biopharmaceuticals. The replacement of chromatography with a single membrane-crystallization unit will lead to >60% CapEx and O&M costs decrease, 30-fold footprint reduction and high-purity solid formulation of mAbs with preserved biological activity.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores